Market Failure and the Poverty of New Drugs in Maternal Health
Open Access
- 22 January 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 5 (1) , e22
- https://doi.org/10.1371/journal.pmed.0050022
Abstract
A new survey finds that only 17 drugs are under active development for maternal health indications, which is less than 3% of the pipeline in cardiovascular health (660 drugs).Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- The Demise of the Blockbuster?New England Journal of Medicine, 2007
- 2006 drug approvals: finding the nicheNature Reviews Drug Discovery, 2007
- The epidemiology of ALS and the role of population-based registriesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2006
- Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 yearsEuropean Journal of Clinical Pharmacology, 2006
- Global and regional burden of disease and risk factors, 2001: systematic analysis of population health dataPublished by Elsevier ,2006
- Stillbirth rates: delivering estimates in 190 countriesThe Lancet, 2006
- System and market failures: the unavailability of magnesium sulphate for the treatment of eclampsia and pre-eclampsia in Mozambique and ZimbabweBMJ, 2005
- Manufacturing uncertainty: Adverse effects of drug development for womenInternational Journal of Law and Psychiatry, 2003
- Teratogenicity of recently introduced medications in human pregnancyObstetrics & Gynecology, 2002
- Access to Essential Drugs in Poor CountriesA Lost Battle?JAMA, 1999